Skip to main content
. 2004 Mar 5;63(11):1372–1378. doi: 10.1136/ard.2003.019422

Figure 1.

Figure 1

 y axis: change in utility reflects how much patients valued elimination of the risk of specific adverse effects or maximal gains in improvement. x axis: range of benefits and risk of adverse effects associated with the DMARDs studied. Yellow: drug characteristics describing benefits; blue: drug characteristics describing common reversible adverse effects; red: drug characteristics describing less common, but potentially more serious, adverse effects.